ACTRN12620000501943
Recruiting
Phase 2
Effectiveness of Prophylactic Hydroxychloroquine on incidence of COVID-19 infection in Front-line Health and Allied Health Care Workers: The COVID-SHIELD Trial
Walter and Eliza Hall Institute of Medical Research0 sites650 target enrollmentApril 22, 2020
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- COVID-19 infection
- Sponsor
- Walter and Eliza Hall Institute of Medical Research
- Enrollment
- 650
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Study participant is willing to provide informed consent
- •2\. Be aged 18\-70 years at the time of consent and in good overall health
- •3\. Health care worker at high risk of COVID\-19 exposure including doctors, nurses and other allied health care workers (such as physiotherapist, radiographer, speech/occupational therapists, personal services assistants, dentist/dental nurse/dental hygienists, aged care workers, optometrist, in general practice or other health care services or paramedic (ambulance) in the following settings:
- •Emergency department
- •COVID\-19 management teams: Outpatient Clinic
- •Inpatient Ward
- •Intensive care unit/ High Dependency Unit (HDU) /Operating Theatre/ Recovery
- •Groups exposed to aerosol generating procedures: eg. anaesthetics/intubation teams
- •Dental Services
- •Aged Care Homes
Exclusion Criteria
- •1\.Prior COVID\-19
- •2\.Presence of any respiratory illness inclusive of fever, cough, dyspnoea, sore throat, rhinorrhoea, nasal stuffiness, headache, myalgia and fatigue
- •3\.Any cardiac arrhythmias, retinal eye disease, liver or kidney disease
- •4\.Any contra\-indication to hydroxychloroquine or chloroquine including allergy or hypersensitivity
- •5\.Any concurrent medication which can prolong QT interval
- •6\.Currently taking or planning to self\-treat with hydroxychloroquine or chloroquine
- •7\.Immunosuppressive conditions or medications
- •8\.Pregnancy or breast feeding
- •9\.Concurrent participation in other COVID\-19 clinical trials
- •10\.Inability to follow study procedures during the trial period
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic HIV-infected patients (HCQ-01) - Hydroxychloroquine studyHIV infectionMedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2007-005057-36-GBMedical Research Council
Completed
Not Applicable
HCQ-01 Trial: evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic human immunodeficiency virus (HIV) infected patientsISRCTN30019040Medical Research Council Clinical Trials Unit (MRC CTU) (UK)90
Not yet recruiting
Phase 3
Efficacy of hydroxychloroquine in graves disease in addition to antithyroid drugs.Health Condition 1: E050- Thyrotoxicosis with diffuse goiterCTRI/2023/07/054894IPQA laboratories
Active, not recruiting
Not Applicable
Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients - NDHIV infection (immunological nonresponders).MedDRA version: 9.1Level: LLTClassification code 10008922EUCTR2009-012499-28-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)40
Completed
Not Applicable
Efficacy and safety of hydroxychloroquine for systemic/cutaneous lupus erythematosus or Sjogren's syndrome patients with annular erythema on the face and/or trunkSystemic/cutaneous lupus erythematosus Sjogren's syndromeJPRN-UMIN000004477Kanazawa University Graduate School of Medical Science10